Oppenheimer Reiterates Outperform on Cellectar Biosciences, Maintains $14 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jeff Jones has reiterated an Outperform rating for Cellectar Biosciences (NASDAQ:CLRB) and maintained a price target of $14.
October 11, 2024 | 5:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer analyst Jeff Jones has reiterated an Outperform rating for Cellectar Biosciences and maintained a price target of $14, indicating confidence in the company's future performance.
The reiteration of an Outperform rating and maintenance of a $14 price target by a reputable analyst suggests positive sentiment and potential upside for Cellectar Biosciences. This could lead to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100